AlphaMadera's AlphaVal page computes Organon & Co.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag OGN as undervalued, fairly valued, or overvalued.

What is Organon & Co.'s fair value?

Fair value for OGN is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value OGN?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from OGN's most recent reported fundamentals.

OGN - Organon & Co.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $11.33 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Strong

Trading 76.6% below fair value

Current Price $13.51

Bear Case $49.48 266.4% upside ($49.48 - $13.51) / $13.51 = 266.4% $4.95 × 12x P/E

Fair Value $57.73 327.5% upside ($57.73 - $13.51) / $13.51 = 327.5% $4.95 × 14x P/E

Bull Case $65.97 388.5% upside ($65.97 - $13.51) / $13.51 = 388.5% $4.95 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

4.95$

Key Value Driver

Normalized P/E multiple (14x base case)

Implied Market Multiple 2.7x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $11.33 from 9 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $57.73 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 588%. Check what costs are being left out of the adjusted number.

ℹ Wall Street's average price target is $11.33 (from 9 analysts). Our estimate is 512% above the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples